Tag: GlobeNewswire

New publication examines how AI can progress beyond task automation to execute enterprise workflows, learn from production outcomes and deliver measurable business results

Live production programs in the Philippines and Mexico reported improvements in revenue, gross margin, worker productivity and revenue per worker during the respective project periods

SAN DIEGO and SINGAPORE, Oct. 01, 2026 (GLOBE NEWSWIRE) — Helport AI Limited (NASDAQ: HPAI) (“Helport AI” or the “Company”), a global artificial intelligence (“AI”) workforce infrastructure company providing intelligent communication software and services to enterprise clients, today announced the publication of a new white paper, “Beyond Deployment: How AI Labor Becomes a High-Performing Digital Workforce.”

The white paper examines a central challenge facing enterprise AI adoption; namely, how to move beyond AI assistants and isolated task automation toward digital workers capable of learning from expert performance, executing complete workflows across enterprise systems and improving against measurable business outcomes. Helport AI defines this operating model as “AI Labor” — the transformation of enterprise knowledge, expert experience, business processes, system execution and production feedback into deployable, governable and continuously improving digital labor capacity.

“The question for enterprise AI is no longer simply what a model can generate or what individual tasks it can automate,” said Guanghai Li, Chief Executive Officer of Helport AI. “We believe the more important question is whether AI can enter a real operating environment, perform meaningful work, learn from outcomes and become more effective over time. It is our belief that this transition — from AI as software to AI as measurable labor capacity — represents an important evolution and is supported by what we have observed in our own production deployments.”

From AI Deployment to Measurable Labor Capacity

The white paper draws on production experience from two, real-world collections programs in the Philippines and Mexico during the month of September. They illustrate two complementary paths for the development of AI Labor.

In the Philippines program, Helport AI focused on improving the quality and effectiveness of work performed by digital workers. The Company’s AI Operation Platform (AOP) learning and optimization system analyzes historical interactions and production outcomes to identify high-performing methods, generate training examples, and test strategies through simulated customer interactions before broader use in live production.

During the reported project period (the month of September):

• Revenue increased 15.71%;
• Gross margin increased 29%;
• The share of calls lasting more than 60 seconds increased from 3.1% to 8.4%, approximately 2.7 times the prior level; and
• The training and production-launch cycle for digital workers was reduced by approximately 50%.

In Mexico, Helport AI focused on expanding the scope of work digital workers could perform. Using Helport AI’s HyprLink cross-system execution capabilities and Unified Communication Platform (UCP) omnichannel engagement technology, digital workers were deployed across workflows involving case analysis, enterprise system interaction, customer outreach, collection-note recording and case-status updates.

During the reported project period, the program achieved 100% case-analysis and omnichannel-contact coverage and 100% collection-note accuracy, while cases handled per worker increased 30% and revenue per worker increased 40%.

Results reflect specific customer deployments and project periods, and customer identities have been omitted for confidentiality. Results may have been affected by case mix, customer composition, operating policies, market conditions and other factors, and have not been independently verified through a controlled study. They should not be interpreted as results that will necessarily be achieved in other customer environments, and should not be relied upon as a promise, projection or guarantee of the Company’s future operating performance, financial results or investment returns.

Building AI That Can Learn, Execute and Improve

The white paper describes an AI Labor architecture built around four interconnected capabilities:

• Learning and optimization: AOP uses historical interactions, simulation, automated scoring and production feedback to identify and continuously refine higher-performing operating strategies.
• Work execution: HyprLink enables digital workers to read information from and take actions within enterprise systems, maintain records and respond to operational exceptions.
• Omnichannel engagement: Helport AI’s communication infrastructure coordinates customer engagement across voice, SMS, email, WhatsApp and other channels.
• Governance and feedback: Permissions, data controls, auditability, human oversight and production outcomes provide controls for deploying and continuously improving digital labor.

The Company’s approach is designed to shift AI from performing isolated actions toward assuming responsibility for broader workflows, while allowing human employees to increasingly focus on supervision, exceptions, judgment-intensive decisions and operating strategy.

As digital workers assume greater responsibility, Helport AI believes governance must develop alongside capability. The white paper describes the Company’s approach to compliance validation, runtime monitoring, auditability, human oversight and data classification, including an AI Data Firewall designed to control how sensitive enterprise information interacts with AI systems.

A Different Measure of Enterprise AI

The white paper argues that enterprise AI should be evaluated not simply by model benchmarks or the number of features deployed, but also by its ability to execute real work reliably and contribute to measurable operating outcomes.

“Deployment should not be viewed as the finish line for enterprise AI; it is the beginning of the learning process,” added Li. “Our objective is to create digital workers that can learn how high-performing employees work, execute across real enterprise environments and continuously improve through production feedback. We believe the defining question for AI Labor is not simply what the AI can do, but whether it can complete the work, complete it correctly, and perform it better the next time.”

The full white paper, “Beyond Deployment: How AI Labor Becomes a High-Performing Digital Workforce,” is available at: https://ir.helport.ai/static-files/a999b4e9-50c3-4ed8-9d51-5aa25a27e900

About Helport AI

Helport AI (NASDAQ: HPAI) is a global AI workforce infrastructure company providing intelligent communication software and services to enterprise clients. Its core asset is the AI Labor System, an industrial-scale platform designed to manufacture, orchestrate, and deliver AI workforce capacity based on measurable business outcomes. Through its AI workforce, Helport AI helps clients drive sales, improve engagement, and reduce costs. The Company’s mission is to transform human expertise into scalable AI labor. Learn more at www.helport.ai.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, statements regarding Helport AI’s business plans, strategies, objectives, expectations regarding the development and adoption of AI Labor, the capabilities and potential applications of the Company’s technologies, and the Company’s expectations regarding the future development and deployment of its products and services. Forward-looking statements in this announcement also include statements regarding the anticipated benefits, scalability, replicability or future performance of the Company’s AI Labor operating model and related technologies (including AOP, HyprLink and UCP), and management’s expectations and beliefs regarding the future direction of enterprise AI adoption, as reflected in the white paper and in the quotations of Company management included in this announcement. The production results described in this announcement and the accompanying white paper reflect historical outcomes from specific customer deployments during specific project periods and are not forward-looking statements, and readers should not assume that such historical results are indicative of, or a guarantee of, future or comparable results in other customer environments or periods. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs.

Investors can identify many of these forward-looking statements by words or phrases such as “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. Actual results may differ materially from those expressed or implied by these forward-looking statements due to various risks and uncertainties. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as may be required by law. Investors are encouraged to review the Company’s filings with the U.S. Securities and Exchange Commission for additional information regarding factors that may affect future results.

Media Contact

Investor Relations
Helport AI Limited
Email: ir@helport.ai
Website: ir.helport.ai

Cooper Brings 21 Years of Water Treatment Experience, from Mine Water Discharge to Drinking Water, Including Five Years Overseeing the West Virginia Rural Water Association’s Emerging Contaminants Program

CORSICANA, Texas, Oct. 01, 2026 (GLOBE NEWSWIRE) — Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced the appointment of Charlie Cooper as Business Development Manager, effective October 1, 2026. In this role, Mr. Cooper will lead efforts to develop and expand Birchtech’s relationships with municipalities, public service districts, and utility operators, with a focus on rural and small water systems.

Mr. Cooper brings 21 years of hands-on water treatment experience, spanning industrial mine water discharge to municipal drinking water. Most recently, he spent five years with the West Virginia Rural Water Association (WVRWA), overseeing its Emerging Contaminants Program and helping systems across the state prepare for new testing, treatment, and regulatory demands. Before joining WVRWA, Mr. Cooper served as a Water Plant Operator for the City of Lewisburg, West Virginia, gaining frontline experience running a public drinking water system. Earlier in his career, Mr. Cooper led the Environmental Department at Alpha Natural Resources, then one of the nation’s largest coal producers, managing water treatment and compliance across 131 mining permits.

Mr. Cooper’s appointment reflects Birchtech’s strategic focus on expanding its water treatment presence across the nation’s nearly 50,000 community water systems, particularly among smaller utilities where compliance pressures remain significant and internal resources are often limited. He will work closely with Birchtech’s operations and R&D teams to identify client needs and connect them with practical, cost-effective solutions.

Management Commentary

“Charlie understands the realities rural water systems face every day, especially the challenge of meeting evolving PFAS regulations on a limited budget,” said Richard MacPherson, Birchtech Chief Executive Officer. “Charlie has spent years helping these systems prepare for emerging contaminants, and that experience is exactly what we need as we work to bring Carbon Rejuvenation™ to smaller utilities that stand to benefit most from its potential cost savings and operational efficiency. We expect that he will help us listen better, respond faster, and deliver solutions that truly fit the communities we serve, as we continue to scale our water business and drive long-term value for my fellow shareholders.”

“Charlie has worked on nearly every side of water treatment, from mine discharge sites to a city drinking water plant to helping rural systems tackle emerging contaminants,” said Dennis Baranik, Director of National Sales at Birchtech. “That kind of range is rare, and it means Charlie knows our customers’ challenges from the inside. We’re excited to put that experience to work for the communities he has served for years.”

About Birchtech Corp.

Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) is a leader in specialty activated carbon technologies delivering innovative solutions for air and water purification to support a cleaner, more sustainable future. The Company provides patented SEA^® sorbent technologies for mercury emissions capture for the coal-fired utility sector and SEA disruptive water purification technologies with a specialization on removing contaminants, including ‘forever chemicals’ such as PFAS, from potable water and industrial wastewater. Backed by a strong intellectual property portfolio and a team of activated carbon experts, Birchtech provides cleaner air to North American communities and is applying this expertise to a novel approach in water purification. To learn more, please visit www.birchtech.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward-looking statements” that are made pursuant to the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are generally identified by using words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. Forward-looking statements in this release include, without limitation, statements relating to expected developments and growth in Birchtech’s business, including the Company’s water treatment growth strategy, the anticipated contributions of Mr. Cooper, and the planned commercialization of its Carbon Rejuvenation™ technology. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. In addition, this release contains time-sensitive information that reflects management’s best analysis only as of the date of this release. Birchtech does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance or other forward-looking statements contained in this release can be found in Birchtech’s periodic filings with the Securities and Exchange Commission or Canadian securities regulators.

Investor Relations Contact:

Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
(949) 259-4987
BCHT@mzgroup.us
www.mzgroup.us

Delray Beach and Miami, FL, Oct. 01, 2026 (GLOBE NEWSWIRE) — VIVIFY Technology, a hydrogen energy company headquartered in Delray Beach, Florida, and Evolution Metals & Technologies Corp. (“EM&T”) (Nasdaq: EMAT), a U.S.-based critical materials and advanced manufacturing company headquartered in Miami, Florida, today announced that they have signed a non-binding letter of intent under which VIVIFY, would, subject to the execution of definitive agreements and satisfaction of applicable conditions deploy behind-the-meter hydrogen power to support EM&T’s planned U.S. rare earth magnet campus, subject to technical validation and definitive agreements. The letter of intent brings together two Florida companies working on the same national problem from opposite ends: the critical materials that American industry and defense depend on, and the power it takes to produce them. There can be no assurance that definitive agreements will be entered into as set forth in the letter of intent or at all.

EM&T is building a non-China supply chain for rare earth permanent magnets, the components that drive electric vehicles, medical imaging equipment, and defense systems. Through operating subsidiaries with more than 18 years of commercial magnet manufacturing history, the company is scaling annual magnet production capacity in Pohang, Republic of Korea, from approximately 1,000 to 10,000 metric tons, supported by a 750-megawatt electrical infrastructure agreement. EM&T is also developing a fully integrated U.S. rare earth magnet campus, with Phase I planned as the largest hydrometallurgical facility in the Western Hemisphere. The expansion comes as new DFARS sourcing requirements for the U.S. defense industrial base take effect on January 1, 2027.

VIVIFY designs near-zero-emission hydrogen power systems deployed behind the meter and independent of the legacy grid. Its Arsenal includes the flagship Hydrogen Oxygen Generator™ (HOG™), the Clean Air Technology™ (CAT™) five-stage emissions control system, and the Flying Pig™, a containerized hydrogen power unit engineered toward 1MW per container and designed to scale by adding modules. Water is the primary fuel input, and VIVIFY’s system is designed to produce output that 99% emission-free, and does not require ongoing fuel resupply is required. VIVIFY’s corporate office and lab are based in Delray Beach, Florida, with manufacturing in Jupiter, Florida, scheduled to begin in January 2027.

Magnet manufacturing and critical materials processing are power-intensive work, and large blocks of reliable power have become one of the hardest inputs for advanced manufacturers to secure. VIVIFY’s modular architecture is designed to allow power capacity to grow alongside production.

Rather than waiting on a single large installation or a utility interconnection timeline, capacity would be added container by container as each phase of production comes online. At EM&T’s planned U.S. rare earth magnet campus, the aim is to keep both halves of the equation, the magnets and the power behind them, American-built and Florida-headquartered.

“Every serious manufacturer in this country is asking the same question right now: where does the power come from? EM&T is rebuilding one of the most important supply chains America has. Our job is to make sure power is never the thing that slows them down,” said Jason Herring, Founder and CEO of VIVIFY Technology.

“Large blocks of reliable power are becoming the constraint no one in advanced manufacturing can ignore. Pairing a domestic critical materials supply chain with domestic, behind-the-meter power is exactly what this moment calls for,” David Wilcox, Executive Chairman of EM&T, said. “Two Florida companies, one mission: End America’s dependence on foreign supply for the materials our industrial base and national defense run on.”

“Florida is open for business. Two great Florida companies are innovating today to solve for tomorrow’s energy needs and critical supply chains.” said U.S. Representative and Candidate for Florida Governor, Byron Donalds. Byron recently toured the VIVIFY facility and met with their engineering team, noting that their technology addresses Florida’s most pressing energy issues: hurricane recovery, rapid residential growth, and data center demands.

About VIVIFY Technology
VIVIFY Technology is a hydrogen energy company headquartered in South Florida. The company designs and develops hydrogen-based energy platforms, including its flagship Hydrogen Oxygen Generator™ (HOG™), the Clean Air Technology™ (CAT™) emissions control system, and the Flying Pig™ containerized power unit, engineered to deliver dependable, dedicated power for the most demanding infrastructure environments in operation today. VIVIFY’s corporate office and lab are located in Delray Beach, Florida, with manufacturing in Jupiter, Florida, beginning in January 2027. Learn more at vivify-technology.com.

About Evolution Metals & Technologies Corp.
Evolution Metals & Technologies Corp. (Nasdaq: EMAT) is a U.S.-based critical materials and advanced manufacturing company for rare earth permanent magnets, battery materials, and related critical minerals and technologies. By leveraging proven commercial-scale operations, advanced processing technologies, and strategic partnerships, EM&T operates what it believes is the only vertically integrated critical materials supply chain spanning end-of-life electronics and batteries, high-grade concentrates, and the manufacture of finished rare earth magnets (including high-performance rare earth magnets) and battery materials. For additional information, please visit https://investors.evolution-metals.com and follow the Company on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the future financial or operating performance of EM&T and may include, without limitation, statements regarding the letter of intent, the collaboration with VIVIFY, the negotiation and execution of definitive agreements, the anticipated terms, structure, timing and benefits of the collaboration, the EM&T’s planned U.S. expansion, and EM&T’s strategy, business plans and growth opportunities. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential,” “plan,” “project,” “target,” “forecast,” or the negatives of these terms or variations of them or similar terminology. These forward-looking statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that EM&T and VIVIFY do not enter into definitive agreements on the terms contemplated by the letter of intent or at all; the risk that VIVIFY’s hydrogen energy systems do not satisfy EM&T’s technical due diligence or the independent or additional validation on which any definitive agreements are expected to be conditioned, or do not perform as expected; the risk that site control or required governmental, utility, environmental and safety authorizations are not obtained; the risk that the anticipated benefits of the collaboration are not realized; EM&T’s ability to execute its business plan, including its planned U.S. expansion, obtain financing, construct and scale facilities, secure feedstock and offtake agreements, obtain necessary permits, certifications and regulatory approvals, manage supply chain disruptions, respond to competitive pressures and address geopolitical and macroeconomic risks; and other risks described in EM&T’s filings with the U.S. Securities and Exchange Commission (the “SEC”). Additional information concerning factors that may affect EM&T’s expectations and projections is contained in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, filed with the SEC on August 17, 2026, including the disclosures under “Risk Factors” therein, and other documents filed or to be filed with the SEC by EM&T. SEC filings are available at www.sec.gov. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date made. Neither EM&T nor VIVIFY, undertakes any obligation to update any forward-looking statement except as required by law.

Media Contacts:

VIVIFY Technology
Ashley Stevenson, Chief Marketing Officer
ashley@vivify-technology.com
888.277.8370
vivify-technology.com

EM&T Investor Relations Contact
Arx Investor Relations
North American Equities Desk
www.arxhq.com
EMAT@arxhq.com

EM&T PR, Media & Global Communications Contact
Phoenix MGMT & Consulting
www.PhoenixMGMTConsulting.com
PR@PhoenixMGMTConsulting.com
888-228-0122

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), an AI-driven robotics solutions provider, today announced the appointment of Dr. Ang Li as Chief Technology Officer. Dr. Li will lead the Company’s technology strategy and AI roadmap, with a focus on advancing autonomous intelligence, AI-powered perception, and edge computing capabilities across the Company’s robotics platforms.

The appointment marks an important step in AMC Robotics’ strategy to build increasingly intelligent and autonomous robotic systems for real-world environments. Drawing on Dr. Li’s expertise in edge AI, distributed machine learning, and embodied intelligence, the Company plans to strengthen the integration of advanced AI models with its robotic hardware and accelerate the translation of emerging AI technologies into scalable commercial robotics applications.

Dr. Li is an Assistant Professor in the Department of Electrical and Computer Engineering at the University of Maryland, College Park, where he will continue in his academic role while serving as Chief Technology Officer of AMC Robotics. Prior to joining the University of Maryland in August 2023, Dr. Li served as a Research Associate at Qualcomm AI Research and previously conducted research at Alibaba DAMO Academy. His research spans edge AI, distributed and federated learning, efficient AI systems, and embodied intelligence, with a particular focus on enabling advanced AI models to operate efficiently and reliably in real-world environments.

Dr. Li holds a Bachelor of Science from Henan University, a Master of Engineering from Peking University, a Master of Science and Ph.D. from the University of Arkansas, and a Ph.D. in Electrical and Computer Engineering from Duke University. His research has been recognized with the NSF CAREER Award, Cisco Research Award, CPAL Rising Star Award, IEEE TCCPS Outstanding Ph.D. Dissertation Award, the ACM KDD Best Student Paper Award, and the Duke ECE Department Outstanding Dissertation Award.

“We are very excited to welcome Dr. Li to the AMC Robotics leadership team,” said Sean Da, Chairman and Chief Executive Officer of AMC Robotics. “AI is becoming increasingly central to the capabilities and differentiation of modern robotic systems. Dr. Li brings deep expertise at the intersection of artificial intelligence, edge computing, and intelligent systems, and we believe his leadership can help accelerate our evolution toward more autonomous, adaptive, and AI-native robotics platforms. His experience will be especially valuable as we advance our existing products, develop new robotic capabilities, and pursue broader commercial applications.”

“Robotics is entering a new phase in which advances in AI can fundamentally expand what machines are able to perceive, reason about, and accomplish in the physical world,” said Dr. Ang Li, Chief Technology Officer of AMC Robotics. “AMC Robotics already has a strong foundation in robotic hardware and real-world applications. I am excited about the opportunity to build on that foundation by bringing advanced AI, edge intelligence, and embodied intelligence more deeply into our platforms. I look forward to working with the team to translate these technologies into practical capabilities and build the next generation of intelligent robotic systems.”

About AMC Robotics Corporation

AMC Robotics (Nasdaq: AMCI) is an AI-driven robotics company focused on developing intelligent, scalable hardware and software solutions. The Company’s quadruped robotic platform, Kyro™, enables industries to automate inspection, security, and operational tasks through autonomous mobility and AI-powered perception and its warehouse logistics sorting robot, NovaArm™ is designed to enhance operational efficiency, improve sorting accuracy, and reduce labor costs for warehouses and distribution centers, addressing the accelerating demand for automation across the U.S. logistics sector.

For more information, please visit www.amcx.ai.

Investors and Media Contact

Susan Xu
Alliance Advisors IR
E: AMCRoboticsIR@allianceadvisors.com

Cautionary Note Regarding Forward Looking Statements

This press release may contain statements that constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the Company’s possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment, potential growth opportunities, and the effects of regulation. These forward-looking statements are based on the Company’s management’s current expectations, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside of the Company’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including statements regarding the management’s expectations, hopes, beliefs, intentions, plans, prospects or strategies. These risks, uncertainties, assumptions, and other important factors include, but are not limited to: (a) challenges in opening operations in new jurisdictions, including but not limited to compliance with local ordinances, obtaining any necessary permits and regulatory oversight; (b) the ability to recognize the anticipated benefits of the new operations; (c) the outcome of any legal proceedings that may be instituted against the Company; (d) the ability to continue to meet the applicable stock exchange listing standards; (e) changes in applicable laws or regulations, including legal or regulatory developments (including, without limitation, accounting considerations); (f) the possibility that AMC Robotics may be adversely affected by other economic, business, and/or competitive factors; (g) AMC Robotics’ estimates of expenses and profitability; (h) buildout and production line commissioning of the Company’s robotic manufacturing facility and the corresponding target completion date; and (i) other risks and uncertainties indicated under “Risk Factors” contained in AMC Robotics’ Annual Report on Form 10-K for the year ended December 31, 2025 and other documents filed or to be filed with the SEC by AMC Robotics. Copies are available on the SEC’s website, www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.

The Company assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company gives no assurance that it will achieve its expectations.

Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC

MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center.

The publication describes two patients with locally advanced pancreatic cancer (LAPC), whose tumors were not surgically removable due to significant complex blood vessel involvement despite receiving extensive prior treatment. Both patients underwent chemotherapy utilizing TAMP-mediated local intra-arterial gemcitabine delivery enabled by RenovoCath. Notably, both patients demonstrated tumor treatment response with reductions in CA 19-9, a marker used to monitor disease activity in pancreatic cancers, and favorable changes on imaging, including resolution of vascular narrowing, without major procedural complications.

“Locally advanced pancreatic cancer remains one of the most difficult cancers to treat, and patients have limited options when standard systemic therapies, like intravenous chemotherapy, are no longer effective,” said Gregory Tiesi, MD, FACS, FSSO, Chief of Surgical Oncology for the Southern Region and Medical Director of Hepatobiliary Surgery at Hackensack Meridian Health Jersey Shore University Medical Center, and lead author of the case series. “This case illustrates that gemcitabine can potentially be safely delivered at the local level via the TAMP platform in patients with complex vascular anatomy and adds to the peer-reviewed evidence supporting further utilization and evaluation of RenovoCath.” Hackensack Meridian Health Jersey Shore University Medical Center has been using the TAMP Platform with the RenovoCath device in its oncology program for over a year.

“Independent, peer-reviewed publications such as this case series provide important clinical evidence supporting the potential of our novel, targeted drug-delivery approach,” said Ramtin Agah, MD, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder. “These findings strengthen the scientific rationale for our drug-delivery platform and support our broader mission to bring meaningful new options to patients with difficult-to-treat tumors, especially as promising pancreatic treatments emerge that could be delivered via TAMP enabled by RenovoCath.”

Publication Details
Title: Trans-Arterial Micro Perfusion in Locally Advanced Pancreatic Cancer: A Case Series and Review of Evidence
Journal: Case Reports in Oncology
Lead Author: Gregory Tiesi, MD, FACS, FSSO
Institution: Hackensack Meridian Health Jersey Shore University Medical Center

About RenovoCath

Based on its FDA clearance, RenovoCath^® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-H-Universal-IFU.pdf.

About RenovoRx, Inc.

RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a standalone device. For its first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, followed by record quarterly revenue of $909,000 in the second quarter of 2026. RenovoRx is actively working to expand the number of medical institutions initiating new RenovoCath orders, including esteemed, high-volume National Cancer Institute-designated centers.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx achieved full enrollment in the TIGeR-PaC trial in August 2026, with completion of the trial expected in the first half of 2027 and topline data readout expected in the second half of 2027.

The IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation (ODD) for pancreatic cancer and bile duct cancer, and oxaliplatin has received ODD for pancreatic cancer, each of which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management and third parties made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies (including the anticipated benefits to the Company of the published case study described herein and potential positive implications for the TAMP therapy platform and RenovoCath), (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology. Statements that are not purely historical are forward-looking statements. These and other forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our commercial plans, research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on such current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “aim,” “goal,” “estimates,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. Risks, uncertainties and assumptions that could cause actual events to differ materially from those projected or indicated by forward-looking statements, include, without limitation: (i) the risk that our commercialization of our TAMP technology (enabled by RenovoCath) may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding-; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed at https://ir.renovorx.com/sec-filings.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRx@KCSA.com

Media Contact:
STiR Communications
Hannah Williams
T: 803-521-1214
hannah@stir-communications.com

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex“) (TSX: CFF) announced today that Spencer Bell has been appointed Chief Financial Officer and Corporate Secretary effective October 1, 2026. Mr. Bell, who joined Conifex in 2021, has held several leadership roles in Conifex’s finance organization, most recently serving as Corporate Finance Manager and prior to that serving as Operations Controller. As Corporate Finance Manager, his efforts were essential to successfully concluding our recently announced Large Enterprise Tariff Loan of up to $30 million and $19 million Business Development Bank of Canada fundings.

“I am delighted to welcome Spencer Bell as CFO given his excellent track record, deep financial expertise, and strong focus on forest sector operating considerations,” commented Ken Shields, Conifex CEO and Chair.

Mr. Shields added “I would also like to extend my sincere thanks to former CFO Trevor Pruden for his extraordinary decade of service to Conifex and for building the strong finance team we have in place today.”

For further information, please contact:

Ken Shields
Chair and CEO
(604) 216-2949

About Conifex Timber Inc.

Conifex and its subsidiaries’ primary business currently includes timber harvesting, reforestation, forest management, sawmilling logs into lumber and wood chips, and value added lumber finishing and distribution. Conifex’s lumber products are sold in the United States, Canadian and Japanese markets. Conifex also produces bioenergy at its power generation facility at Mackenzie, BC.

LOS ANGELES, Oct. 01, 2026 (GLOBE NEWSWIRE) — RBB Bancorp (NASDAQ: RBB) and its bank subsidiary, Royal Business Bank (the “Bank”), collectively referred to herein as the “Company”, today announced that it will release financial results for its third quarter ended September 30, 2026 after the markets close on Monday, October 19, 2026.

Management will hold a conference call at 11:00 a.m. Pacific Time/2:00 p.m. Eastern Time on Tuesday, October 20, 2026, to discuss the Company’s financial results.

To listen to the conference call, please dial 1-888-506-0062 or 1-973-528-0011, passcode 889260, Conference ID RBBQ326. A replay of the call will be made available at 1-877-481-4010 or 1-919-882-2331, passcode 54597, approximately one hour after the conclusion of the call and will remain available through November 3, 2026.

Additionally, interested parties can listen to a live webcast of the call in the “Investor Relations” section of the Company’s website at www.royalbusinessbankusa.com.  This webcast will be recorded and available for replay on the Company’s website approximately two hours after the conclusion of the conference call.

Corporate Overview

RBB Bancorp is a community-based financial holding company headquartered in Los Angeles, California. As of June 30, 2026, the Company had total assets of $4.3 billion. Its wholly-owned subsidiary, Royal Business Bank, is a full service commercial bank, which provides business banking products and services predominantly to Asian-centric communities through 24 branches and one loan production office located in California, Nevada, New York, Illinois, New Jersey and Hawaii. Bank products and services include commercial and investor real estate loans, business loans and lines of credit, SBA 7A and 504 loans, 1-4 single family residential loans, trade finance, wealth management and a full range of depository accounts, including specialized services such as remote deposit, E-banking, mobile banking and treasury management services. The Bank has nine branches in Los Angeles County, two branches in Ventura County, one branch in Orange County, and one loan production office in the San Francisco Bay area in California; one branch in Las Vegas, Nevada; three branches and one loan operation center in Brooklyn, three branches in Queens, and one branch in Manhattan in New York; one branch in Edison, New Jersey; two branches in Chicago, Illinois; and, one branch in Honolulu, Hawaii. The Company’s administrative and lending center is located at 1055 Wilshire Blvd., Los Angeles, California 90017, and its operations center is located at 7025 Orangethorpe Ave., Buena Park, California 90621. The Company’s website address is www.royalbusinessbankusa.com.

Contacts

Lynn Hopkins, EVP and Chief Financial Officer, (213) 716-8066

The Company Significantly Increased Its Repurchase Volume Due to Market Conditions

WEST PALM BEACH, FL, Oct. 01, 2026 (GLOBE NEWSWIRE) — AVAX One Technology Ltd. (NASDAQ: AVX) (“AVAX One” or the “Company”), today announced an update on its $40 million share repurchase program. In the month of September 2026, the Company repurchased 333,500 of its common shares at an average purchase price per share of $5.36, including all fees and commissions. These repurchases bring AVAX One’s total repurchases of its common shares as of September 30, 2026, to 836,743 (as adjusted to reflect the Company’s one-for-twelve reverse stock split effected on June 15, 2026) since November 2025. Approximately $33.9 million remains available under the program.

“We believe there is a meaningful disconnect between the share price and the intrinsic value of AVAX One,” said Pete Wylie, Interim Chief Executive Officer and Chief Operating Officer of AVAX One. “Share repurchases represent one of the most direct ways we can demonstrate conviction in the long-term value of what we’re building at AVAX One. As long as this dislocation persists, we intend to continue leaning in. Our strong balance sheet gives us the flexibility to allocate capital opportunistically where we believe it can create the greatest long-term value per share.”

Repurchases under the program may be made from time to time through open market purchases or other means permitted under applicable securities laws and regulations. The timing and amount of repurchases will depend on market conditions, capital allocation priorities, regulatory requirements and other corporate considerations. The Company is not obligated to repurchase any specific number of shares, and the program may be modified, suspended or discontinued at any time.

About AVAX One Technology Ltd.

AVAX One Technology Ltd. (NASDAQ: AVX) is a digital infrastructure company accelerating the transition to an onchain financial economy. The Company maintains a strategic Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation. It also operates bitcoin mining facilities and develops modular data centers. These three pillars give public market investors unique exposure to both the onchain economy and the digital infrastructure layer. For more information, please visit www.avax-one.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of words such as “anticipate,” “expect,” “intend,” “plan,” “could,” “may,” “will,” “would,” “believe,” “estimate,” “target,” “project,” and other words of similar meaning. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: risks relating to the Company’s operations and business, including the highly volatile nature of the price of Bitcoin, AVAX, and other digital assets, and the risk that the price of the Company’s securities may be highly correlated to the price of the digital assets it holds; plans to repurchase the Company’s common shares and the timing and amount of any such repurchases; increased competition in the data center, AI/HPC, and digital asset industries; and legal, commercial, regulatory, and technical uncertainties affecting the Company’s business, as well as those risks and uncertainties identified in the Company’s filings with the U.S. Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, whether as a result of new information, future events, or otherwise.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
AVX@elevate-ir.com

Media Contact
Ethan Lyle
Prospero
avax-one@prospero.agency

Production deliveries begin in October with completion expected by the end of November as KULR expands its role in the U.S. defense drone supply chain

HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a developer of safe, high-power energy systems that enable physical AI across space, defense, drones, data centers, robotics, and other mission-critical applications, today announced that it has received more than $1 million in production purchase orders for high-performance battery systems supporting the U.S. Department of War’s (DoW) Drone Dominance Program.

Deliveries are scheduled to begin in October 2026, with KULR expecting to complete all shipments by the end of November 2026, providing near-term revenue visibility and demonstrating the Company’s ability to move defense programs into production.

The Drone Dominance Program is a $1.1 billion, multi-phase DoW initiative focused on accelerating the procurement and fielding of small unmanned aerial systems. KULR believes its position at the battery-system level creates an opportunity to support increasing production volumes as participating platforms advance through the program.

The production orders also represent an important validation of KULR’s investment in Forge 2, its new manufacturing facility in Houston, Texas, as the Company transitions customer programs from qualification into scaled production. Forge 2 increases KULR’s capacity to support defense drones and other autonomous platforms, positioning the Company as an important high-volume domestic supplier of battery systems designed to meet NDAA requirements as the first DoW compliance deadline approaches in 2027.

“These purchase orders mark another meaningful step in KULR’s expansion within the defense drone market,” said Michael Mo, Chief Executive Officer of KULR Technology Group. “Our focus is execution — building and delivering advanced battery systems at the volumes our customers require. As U.S. drone production scales, successful execution positions KULR to support larger requirements and additional platform opportunities.”

Rising demand for KULR’s high-performance battery systems reflects accelerating U.S. defense investment in next-generation unmanned systems, where power, reliability, safety, and performance are mission-critical. KULR’s technology is engineered to meet these demanding requirements across advanced UAS platforms.

Safe Harbor Statement
This release contains certain forward-looking statements based on our current expectations, intentions and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All such forward-looking statements that are provided by management in this release are based on information available at this time, and management expects that internal expectations may change over time. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Except as otherwise required by applicable law, we assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

About KULR Technology Group, Inc.
KULR Technology Group, Inc. (NYSE American: KULR) is an energy-systems platform company that designs and manufactures safe, high-power battery solutions for physical AI and other mission-critical applications. Its KULR ONE® platform integrates advanced battery architecture, thermal management, safety engineering, battery management systems, and power electronics to serve space and defense, drones and electric aviation, AI data-center backup, robotics, and Energy-as-a-Service markets. Based in Webster, Texas, KULR is scaling domestic production to support the growing energy demands of physical AI and autonomous systems. Learn more at KULR.ai.

Find KULR: Website | X | Telegram | LinkedIn | Instagram | TikTok | Facebook

Investor Relations:
KULR Technology Group, Inc.
Email: ir@kulr.ai

Bank of North Dakota’s Roughrider Coin is the first live use case on the platform, supported by VersaBank, Solana and Fireblocks

MILWAUKEE, Oct. 01, 2026 (GLOBE NEWSWIRE) — Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology, today announced that its digital asset platform is live with financial institution clients, marking a significant milestone in the commercialization of stablecoin-enabled banking and payments.

The platform’s first live use case is Roughrider Coin, Bank of North Dakota’s dollar-backed stablecoin designed to enable more efficient money movement across the state’s interbank network. VersaBank serves as issuer for Roughrider Coin, Fireblocks is providing secure digital asset infrastructure and tokenization services, and transactions are processed on the Solana blockchain.

“The launch of our digital asset platform is an important milestone for Fiserv and the financial institutions we serve,” said Sunil Sachdev, Head of Embedded Finance and Digital Assets at Fiserv. “By moving from concept to production with leading institutions, we are helping clients unlock new efficiencies in banking and payments while maintaining the trust, security and regulatory standards they expect.”

Participating banks and credit unions will access Roughrider Coin through Commercial Center, Fiserv’s commercial online banking system that financial institution clients rely on today for traditional interbank money movement.

Roughrider Coin Launches as First Live Use Case

Bank of North Dakota is using the Fiserv platform’s issuance, reserve, custody and settlement infrastructure to deploy Roughrider Coin across the state’s banking and payments workflows. The dollar-backed stablecoin gives more than 90 participating banks and credit unions in North Dakota a more efficient way to conduct bank-to-bank transactions while establishing a foundation for additional digital money use cases.

“Bank of North Dakota proudly works alongside our financial partners to strengthen agriculture, commerce and industry across our state,” said Don Morgan, chief executive officer of Bank of North Dakota. “Launching Roughrider Coin with Fiserv builds on that legacy by giving our partner community banks and credit unions a new tool to move money more efficiently across North Dakota’s interbank network. We are proud to lead this next chapter in banking innovation while supporting the continued strength, resilience and relevance of North Dakota’s financial industry.”

VersaBank, a North American leader in business-to-business digital banking and digital asset technology, issues Roughrider Coin and provides custody services. Its role includes minting, burning, custody and reserve asset management—core functions that enable financial institutions to operate stablecoins within a nationally regulated framework.

“VersaBank is proud to partner with Fiserv to build and operate the first product on its digital asset platform,” said David Taylor, Founder and President, VersaBank. “Pairing Fiserv’s scale with VersaBank’s regulated digital asset capabilities gives the industry a trusted foundation to bring stablecoins into established banking and payment systems.”

The Fiserv Digital Asset Platform helps financial institutions, corporates, marketplaces and fintechs enable emerging stablecoin use cases, including stablecoin card issuance, cross-border payments, programmable commerce and treasury automation. The platform also supports tokenized deposits, global currency account services, including U.S. dollar accounts for financial institutions worldwide.

About Fiserv
Fiserv, Inc. (NASDAQ: FISV), a Fortune 500 company, is a global leader uniting commerce and finance. The company powers sustained growth and innovation at scale for financial institutions and businesses worldwide across payments, account processing, digital banking, merchant acquiring, network services, e-commerce, and Clover®, the all-in-one business management platform. Fiserv is a member of the S&P 500® Index and one of FORTUNE® America’s Most Innovative Companies. Visit fiserv.com and follow on social media for more information and the latest company news. 

For more information contact:

Media Relations:
Chase Wallace
Director, External Communications
Fiserv
chase.wallace@fiserv.com